A. Godard, G. Kalot, M. Privat, M. Bendellaa, B. Busser, Karl David Wegner, F. Denat, X. Le Guevel, J.-L. Coll, C. Paul, E. Bodio, C. Goze, L. Sancey
- Using fluorescence-guided surgery (FGS) to cytoreductive surgery helps achieving complete resection of microscopic ovarian tumors. The use of visible and NIR-I fluorophores has led to beneficial results in clinical trials; however, involving NIR-II dyes seems to outperform those benefits due to the deeper tissue imaging and higher signal/noise ratio attained within the NIR-II optical window. In this context, we developed NIR-II emitting dyes targeting human epidermal growth factor receptor 2 (HER2)-positive ovarian tumors by coupling water-soluble NIR-II aza-BODIPY dyes to the FDA-approved anti-HER2 antibody, namely, trastuzumab. These bioconjugated NIR-II-emitting dyes displayed a prolonged stability in serum and a maintained affinity toward HER2 in vitro. We obtained selective targeting of HER2 positive tumors (SKOV-3) in vivo, with a favorable tumor accumulation. We demonstrated the fluorescence properties and the specific HER2 binding of the bioconjugated dyes in vivo and thusUsing fluorescence-guided surgery (FGS) to cytoreductive surgery helps achieving complete resection of microscopic ovarian tumors. The use of visible and NIR-I fluorophores has led to beneficial results in clinical trials; however, involving NIR-II dyes seems to outperform those benefits due to the deeper tissue imaging and higher signal/noise ratio attained within the NIR-II optical window. In this context, we developed NIR-II emitting dyes targeting human epidermal growth factor receptor 2 (HER2)-positive ovarian tumors by coupling water-soluble NIR-II aza-BODIPY dyes to the FDA-approved anti-HER2 antibody, namely, trastuzumab. These bioconjugated NIR-II-emitting dyes displayed a prolonged stability in serum and a maintained affinity toward HER2 in vitro. We obtained selective targeting of HER2 positive tumors (SKOV-3) in vivo, with a favorable tumor accumulation. We demonstrated the fluorescence properties and the specific HER2 binding of the bioconjugated dyes in vivo and thus their potential for NIR-II FGS in the cancer setting.…
MetadatenAutor*innen: | A. Godard, G. Kalot, M. Privat, M. Bendellaa, B. Busser, Karl David WegnerORCiD, F. Denat, X. Le Guevel, J.-L. Coll, C. Paul, E. Bodio, C. Goze, L. Sancey |
---|
Dokumenttyp: | Zeitschriftenartikel |
---|
Veröffentlichungsform: | Verlagsliteratur |
---|
Sprache: | Englisch |
---|
Titel des übergeordneten Werkes (Englisch): | Journal of Medicinal Chemistry |
---|
Jahr der Erstveröffentlichung: | 2023 |
---|
Organisationseinheit der BAM: | 1 Analytische Chemie; Referenzmaterialien |
---|
| 1 Analytische Chemie; Referenzmaterialien / 1.2 Biophotonik |
---|
Verlag: | ACS Publications |
---|
Jahrgang/Band: | 66 |
---|
Ausgabe/Heft: | 7 |
---|
Erste Seite: | 5185 |
---|
Letzte Seite: | 5195 |
---|
DDC-Klassifikation: | Naturwissenschaften und Mathematik / Chemie / Analytische Chemie |
---|
| Technik, Medizin, angewandte Wissenschaften / Ingenieurwissenschaften / Ingenieurwissenschaften und zugeordnete Tätigkeiten |
---|
Freie Schlagwörter: | Antibody conjuagtes; Bioimaging; Fluorescent dye; In vivo imaging; NIR-II; Ovarian cancer |
---|
Themenfelder/Aktivitätsfelder der BAM: | Chemie und Prozesstechnik |
---|
| Material |
---|
| Material / Materialdesign |
---|
DOI: | 10.1021/acs.jmedchem.3c00100 |
---|
ISSN: | 0022-2623 |
---|
Verfügbarkeit des Dokuments: | Datei im Netzwerk der BAM verfügbar ("Closed Access") |
---|
Datum der Freischaltung: | 13.04.2023 |
---|
Referierte Publikation: | Ja |
---|
Datum der Eintragung als referierte Publikation: | 13.04.2023 |
---|